I believe this has not been posted here, Yang and Dhody paper ??( Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab ) ???

https://pubmed.ncbi.nlm.nih.gov/33079180/

I might be wrong ... In any case:

Quote:

---

Methods: 23 hospitalized severe/critical COVID-19 patients received 700mg leronlimab subcutaneously, repeated after seven days in 17/23 patients still hospitalized. 18/23 received other experimental treatments, including convalescent plasma, hydroxychloroquine, steroids, and/or tocilizumab. 5/23 received leronlimab after blinded placebo-controlled trials of remdesivir, sarilumab, selinexor, or tocilizumab . Outcomes and results were extracted from medical records.

---

Quote:

---

Results: Mean age was 69.5 ±14.9 years. 20/23 had significant co-morbidities . At baseline, 22/23 were receiving supplemental oxygen (3/23 high flow, 7/23 mechanical ventilation). Blood showed markedly elevated inflammatory markers (ferritin, D-dimer, C-reactive protein) and elevated neutrophil:lymphocyte ratio. By day 30 after initial dosing, 17/23 were recovered, 2/23 were still hospitalized, and 4/23 had died. Of the 7 intubated at baseline, 4/7 were fully recovered off oxygen, 2/7 were still hospitalized, and 1/7 had died.

---

In a nutshell: Death rate: 17.4% minimum - 26.1% maximum

Recovery rate: 73.9% minimum - 82.6% maximum

I say this is excellent !!!!